Treatment of fungal infections in neutropenic children

Current Opinion in Pediatrics

Volumn 11, Issue 1, 1999, Pages 47-55

  Lehrnbecher, Thomas ^a   Groll, Andreas H ^a   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; CYTOKINE; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PARACETAMOL; PETHIDINE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ADOLESCENT; ASPERGILLOSIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHEMOTHERAPY; CHILD; CHILDHOOD DISEASE; CHILL; DRUG INFUSION; FEVER; HEART ARRHYTHMIA; HUMAN; IMMUNE DEFICIENCY; INFANT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAGNESIUM DEFICIENCY; MICTURITION DISORDER; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; POTASSIUM DEPLETION; PRIORITY JOURNAL; REVIEW; RIGOR; RISK FACTOR; UREMIA; VIRUS INFECTION;

CHILD; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; NEUTROPENIA;

EID: 0032995693     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199902000-00010     Document Type: Review

References (112)

1. Ritter J, Roos N: Special aspects related to invasive fungal infections in children with cancer. In Bailleres Clinical Infectious Diseases. Edited by Meunier F. London: 1995; 179-204.
2. Pfaller MA: Epidemiology of candidiasis. J Hosp Infect 1995, 30(suppl):329-338.
3. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33:23-32.
4. Akova M, Akalin HE, Uzun O, Gur D: Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991, 10:598-599.
5. Metzger S, Hofmann H: Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole. Mycoses 1997, 40:56-63.
6. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al.: Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996, 174:821-827.
7. Wiley J, Smith N, Leventhal B, Graham M, Strauss L, Hurwitz C, et al.: Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis. J Clin Oncol 1990, 8:280-286.
8. Horn R, Wong B, Kiehn TE, Armstrong D: Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985, 7:646-655.
9. Marcon MJ, Powell DA: Human infections due to Malassezia spp. Clin Microbiol Rev 1992, 5:101-119.
10. Chanock S: Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993, 7:771-794.
11. Hertenstein B, Kern WV, Schmeiser T, Stefanic M, Bunjes D, Wiesneth M, et al.: Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994, 68:21-26.
12. Cushing D, Bustamante C, Devlin A: Aspergillus infection prophylaxis: Amphotericin B-nose spray, a double-blind trial [abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy 1991. Chicago: 1991:222.
13. Rousey S, Russler S, Gottlieb M, Ash R: Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogeneic marrow recipients. Am J Med 1991, 91:484-492.
14. Trigg ME, Morgan D, Burns TL, Kook H, Rumelhart SL, Holida MD, Giller RH: Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Bone Marrow Transplant 1997, 19:43-47.
15. Jeffery GM, Beard ME, Ikram RB, Chua J, Allen JR, Heaton DC, Hart DN, Schousboe MI: Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991, 90:685-692.
16. Meunier-Carpentier F, Snoeck R, Gerain J, Muller C, Klastersky J: Amphotericin B nasal spray as prophylaxis againt aspergillosis in patients with neutropenia. N Engl J Med 1984, 311:1056-1062.
17. Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, et al.: Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991, 13:496-503.
18. Bodey G: The emergence of fungi as major hospital pathogens. J Hosp Infect 1988, 11:411-426.
19. Anaissie E: Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992, 14(suppl 1):S43-53.
20. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
21. Nguyen MH, Peacock JE, Jr., Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al.: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
22. Berenguer J, Allende M, Lee J, Garrett K, Lyman C, Ali N, et al.: Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolonone-induced immunosuppression. Am J Respir Crit Care Med 1995, 152:1079-1086.
23. McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, et al.: Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993, 17:397-404.
24. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al.: Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992, 11:99-109.
25. Anaissie EJ, Bodey GP, Rinaldi MG: Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989, 8:323-330.
26. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al.: Trichosporon beigelii, an emerging pathogen resistant to Amphotericin B. J Clin Microbiol 1990, 28:1616-1622.
27. Walsh T, Gonzalez C, Lyman C, Chanock S, Pizzo P: Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996, 11:187-290.
28. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G: The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988, 67:77-83.
29. Reynolds ES, Tomkiewicz ZM, Dammin GJ: The renal lesion related to amphotericin B treatment for coccidiomycosis. Med Clin North Am 1963, 47:1149-1154.
30. Benson JM, Nahata MC: Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 1989, 33:1989-1993.
31. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL: Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987, 155:766-774.
32. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711-718. The authors of this prospective, parallet, comparative, multicenter trial [32·,33·,34·] provide evidence for an equivalent or possibly superior efficacy of liposomal amphotericin compared with conventional AmB with regard to resolution of fever of unknown origin.
33. White MH, Bowden RA, Sandier E: Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B in the empiric treatment of febrile neutropenic patients [abstract]. Blood 1996, 88(suppl 1):302a. The authors of this prospective, parallet, comparative, multicenter trial [32·,33·,34·] provide evidence for an equivalent or possibly superior efficacy of lipid formulation of amphotericin compared with conventional AmB with regard to resolution of fever of unknown origin.
34. Walsh TJ, Bodensteiner D, Himenz J: A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients [abstract]. Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society for Microbiology, 1997:381. The authors of this prospective, parallet, comparative, multicenter trial [32·,33·,34·] provide evidence for an equivalent or possibly superior efficacy of liposomal amphotericin compared with conventional AmB with regard to resolution of fever of unknown origin.
35. Groll AH, Piscitelly TJ, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998, 44:343-500. In this state-of-the-art review, the authors address the clinical pharmacology of different agents for antifungal therapy and new compounds that are currently under investigation and discuss putative targets for antifungal drug development.
36. Sawaya BP, Briggs JP, Schnermann J: Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995, 6:154-164.
37. Arning M, Scharf RE: Prevention of amphotericin B induced nephrotoxicity by loading with sodium-chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989, 67:1020-1028.
38. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983, 75:476-481.
39. Groll AH, Muller FM, Piscitelli SC, Walsh TJ: Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998, 210:264-273.
40. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and anti-fungal therapy for cancer patients with prolonged fever and granutocytopenia. Am J Med 1982, 72:101-111.
41. European Organization for the Research and Treatment of Cancer International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668-672.
42. Heinemann V, Bosse D, Jehn U, Kahny B, Wachholz K, Debus A, et al.: Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother 1997, 41:1275-1280. This study describes the pharmacokinetic characteristics of the liposomal formulation of amphotericin B (AmBisome) and compares them with the pharmacokinetics of amphotericin B deoxycholate.
43. Walsh TJ, Bekersky I, Teldani V: Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998, 42:2391-2398. This phase I study demonstrated that AmBisome could be safely administered to neutropenic cancer patients at doses as high as 7.5 mg/kg without causing significant toxicities. The results suggest that breakthrough infections are rare when this formulation is used for empirical therapy in cancer and marrow transplant patients.
44. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD: Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995, 39:2042-2047.
45. White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997, 24:635-642. This retrospective study suggests that in the treatment of aspergillosis, AmB colloidal dispersion causes fewer nephrotoxic effects than AmB, and the efficacy of the colloidal dispersion formulation is at least comparable with that of the noncolloidal formulation.
46. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996, 173:1208-1215.
47. Herbrecht R: Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997, 16:74-80.
48. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995, 21:1145-1153.
49. Herbrecht R, Letscher V, Andres E: Zygomycosis treated with amphotericin B colloidal dispersion: a review of 22 cases [abstract]. Blood 1996, 88(suppl 1):502.
50. Noskin GA, Pietrielli L, Coffey G, Gurwith M, Liang U: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998, 26:461-467. This study suggests that AmB colloidal dispersion is safe and effective for treating patients with Candida infections subsequent to bone marrow transplantation, hematologic malignancies, solid tumors, solid-organ transplantation, or other severe underlying disorders.
51. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, Sherman JW: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J Infect Dis 1991, 164:418-421.
52. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396. In this open-label, single-patient, emergency-use study of patients with fungal infections refractory to or who were intolerant of conventional antifungal therapy, the safety and antifungal efficacy of AmB lipid complex were evaluated. The findings support the use of the lipid formulation in the treatment of invasive fungal infections in these patients.
53. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315-321.
54. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, et al.: Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997, 41:2201-2208.
55. Hiemez JW, Lister J, Anaissie EJ: Emergency use of amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B [abstract]. Blood 1995, 86(suppl 1):849a.
56. Mehta J, Kelsey S, Chou P: Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematological malignancies. Bone Marrow Transplant 1997, 20:39-43.
57. Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SJ, et al.: Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997, 41:1944-1948. The safety, tolerance, and pharmacokinetics of AmB lipid complex were studied in a cohort of pediatric cancer patients. AmB lipid complex administered in multiple doses to children was safe, was characterized by a steady state attainable within 1 week of therapy, and was effective in treatment of hepatosplenic candidiasis.
58. Wingard JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997, 19:343-347. The results of this evaluation of 59 bone marrow transplant recipients with presumed or confirmed fungal infections indicate that AmB lipid complex injection appears to be less nephrotoxic than conventional AmB and is an effective treatment.
59. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, et al.: Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993, 7:829-835.
60. Meunier F, Prentice HG, Ringden O: Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991, 28 (suppl B):83-91.
61. Mills W, Chopra R, Linch DC, Goldstone AH: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994, 86:754-760.
62. Ng TT, Denning DW: Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 995, 155:1093-1098.
63. Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J: Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994, 14:S10-14.
64. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al.: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991, 28 (suppl B):73-82.
65. Anaissie EJ, White M, Uzun O: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatments of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society of Microbiology, 1995:330.
66. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463-1471. In this study, HIV-infected patients with cryptococcal meningitis were randomly assigned to treatment with either liposomal AmB (AmBisome) or standard AmB, each followed by fluconazole. Treatment with AmBisome resulted in a significantly earlier cerebrospinal fluid culture conversion than treatment with AmB, had equal clinical efficacy, and was significantly less nephrotoxic.
67. Pasic S, Flannagan L, Cant AJ: Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant 1997, 19:1229-1232.
68. Dornbusch HJ, Urban CE, Pinter H, Ginter G, Fotter R, Becker H, et al.: Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr Hematol Oncol 1995, 12:577-586.
69. Ringden O: Clinical use of AmBisome with special emphasis on experience in children. Bone Marrow Transplant 1993, 12 (suppl 4):S149-S150.
70. Zoubek A, Emminger W, Emminger-Schmidmeier W, Peters C, Pracher E, Grois N, Gadner H: Conventional vs. liposomal amphotericin B in immunosuppressed children [letter]. Pediatr Hematol Oncol 1992, 9:187-190.
71. Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG: Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984, 144:549-551.
72. Shepp DH, Klosterman A, Siegel MS, Meyers JD: Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985, 152:1257-1263.
73. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263-272.
74. De Pauw BE, Meis JF: Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer 1998, 6:31-38.
75. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al.: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996, 23:964-972.
76. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA, et al.: Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin: the Multicenter Fluconazole Study Group. J Pediatr 1995, 127:322-328.
77. Slavin M, Osborne B, Adams R, Levenstein M, Schoch H, Feldman A, Meyers J, et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
78. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
79. Ninane J: A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies: Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994, 13:330-337.
80. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al.: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Ann Intern Med 1993, 118:495-503.
81. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al.: Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B: the GIMEMA Infection Program. Ann Intern Med 1994, 120:913-918.
82. Yamac K, Senol E, Haznedar R: Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995, 71:284-286.
83. Walsh TJ, White M, Seibel N, Arnow P, Wiley J, Melcher G: Efficacy of early empirical fluconazole therapy in febrile neutropenic patients: results of a randomized, double-blind, placebo-controlled, multicenter trial. Program addendum and late-breaker abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society for Microbiology; 1996.
84. Bohme A, Ganser A, Hoelzer D: Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995, 71:311-312.
85. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H: Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:685-693.
86. Le Conte P, Joly V, Saint-Julien L, Gillardin JM, Carbon C, Yeni P: Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Respir Dis 1992, 145:424-429.
87. Zhou H, Lee P, Moore LRC, Wu J, Woestenborghs R, Hassell AE, et al.: Pharmacokinetic study of itraconazole in patients with advanced HIV infection. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society for Microbiology, 1996:11.
88. Boogaerts M, Michaux JL, Bosly A, Van Hoof A, Jacqmin P, Van Peer A, et al.: Pharmacokinetics and safety of seven days intravenous itraconazole followed by two weeks oral itraconazole solution in patients with hematological malignancies. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society for Microbiology, 1996:17.
89. Denning D, Lee J, Hostetler J, Pappas P, Kaufman C, Dewnup D, et al.: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994, 97:135-144.
90. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al.: The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988, 31:476-485.
91. Aanpreung P, Veerakul G: Itraconazole for treatment of oral candidosis in pediatric cancer patients. J Med Assoc Thai 1997, 80:358-362.
92. de Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JK, van Boxtel CJ, van Ketel RJ, Stam J: Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992, 6:185-190.
93. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome: National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15-21. In a double-blind, multicenter trial it was shown that consolidation therapy with fluconazole in patients with AIDS-associated cryptococcal meningitis is associated with a higher rate of cerebrospinal fluid sterilization compared with itraconazole therapy. Itraconazole, however, may be a suitable alternative for patients unable to take fluconazole.
94. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK: Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987, 5:1985-1993.
95. Karp JE, Burch PA, Merz WG: An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988, 85:203-206.
96. Francis P, Walsh T: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetic, and antifungal therapy. Cin Infect Dis 1992, 15:1003-1018.
97. Groll AH, Walsh TJ: Potential new antifungal agents. Curr Opin Infect Dis 1997, 10:449-458. This review discusses new candidates for systemic antifungal therapy that are currently under investigation.
98. Boutati E, Maltezou HC, Lopez-Berestein G, Vartivarian SE, Anaissie EJ: Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. American Society for Microbiology, 1995:330.
99. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (r metHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
100. Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579-583.
101. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon gamma. J Infect Dis 1992, 166:668-673.
102. Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH: Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. Clin Lab Haematol 1997, 19:39-47.
103. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S: Role of granulocyte macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993, 17:705-707.
104. Namunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers J, Owens A, Day R, et al.: Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993, 82:1422-1427.
105. Hennequin C, Benkerrou M, Gaillard JL, Blanche S, Fraitag S: Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child [letter]. Clin Infect Dis 1994, 18:490-491.
106. Romani L, Mencacci A, Grohmann U, Mocci S, Mosci P, Puccetti P, Bistoni F: Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med 1992, 176:19-25.
107. Kawakami K, Tohyama M, Xie Q, Saito A: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996, 104:208-214.
108. Magee DM, Cox RA: Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun 1996, 64:3609-3613.
109. Rodriguez-Adrian U, Grazziutti ML, Rex JH, Anaissie EJ: The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998, 26:1270-1278.
110. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ: Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 1995, 10:188-193.
111. Grigg A, Vecchi L, Bardy P, Szer J: G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepis. Aust NZ J Med 1996, 26:813-818.
112. Lehmbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ: Therapy-induced alterations in host defense in children receiving chemotherapy. J Pediatr Hematol Oncol 1997, 19:399-417. The authors address the alterations in host defense that occur as a consequence of therapeutic intervention in children with cancer.